{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:38:36Z","timestamp":1792291116943,"version":"4.4.0"},"reference-count":38,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007632","name":"Changhua Christian Hospital","doi-asserted-by":"crossref","award":["114-CCH-IRP-007, 113-CCH-IRP-007, 112-CCH-IRP-033"],"award-info":[{"award-number":["114-CCH-IRP-007, 113-CCH-IRP-007, 112-CCH-IRP-033"]}],"id":[{"id":"10.13039\/501100007632","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD), including Crohn\u2019s disease (CD) and ulcerative colitis (UC), are characterized by chronic inflammation of the gastrointestinal tract. Antinuclear antibodies (ANAs), which are autoantibodies directed against nuclear components, are commonly present in various autoimmune disorders. We investigated the prevalence and clinical significance of ANAs in Taiwanese patients with IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From January 2017 to December 2024, ANA status was checked at initial diagnosis of IBD in patients from a medical center in central Taiwan. Risk factors for ANA positivity were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 166 patients in this study, 57 had CD and 109 had UC. ANA test results were positive (titers of \u2265 1:160) in 26 patients (15.7%). Older age at disease diagnosis (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.05) and a diagnosis of UC (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.05) were statistically significant risk factors for ANA positivity. Gender (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.31), use of advanced therapy (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.66), and the presence of extraintestinal manifestations (EIMs) (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.14) were not associated with ANA positivity. The response to anti-tumor necrosis factor therapy did not differ between ANA-positive and ANA-negative patients (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.34). The most frequent ANA staining patterns were AC1, AC3, and AC4.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that although ANA positivity is relatively common among Taiwanese patients with IBD, particularly among older UC patients. Further validation is required to explore the clinical implications of ANA positivity in Asian population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.20474","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:56:26Z","timestamp":1764320186000},"page":"e20474","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence and association testing of antinuclear antibodies and inflammatory bowel disease in Taiwan"],"prefix":"10.7717","volume":"13","author":[{"given":"Tsai-Min","family":"Yang","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Ting","family":"Lu","sequence":"additional","affiliation":[{"name":"Frontier Molecular Medical Research Center in Children, Changhua Christian Children Hospital, Changhua, Taiwan"},{"name":"Department of Pediatrics, Changhua Christian Children Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-2245","authenticated-orcid":true,"given":"Hsu-Heng","family":"Yen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan"},{"name":"Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5936-7112","authenticated-orcid":true,"given":"Yang-Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"6","key":"10.7717\/peerj.20474\/ref-1","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1053\/j.gastro.2011.02.012","article-title":"Interactions between the host innate immune system and microbes in inflammatory bowel disease","volume":"140","author":"Abraham","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.7717\/peerj.20474\/ref-2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"5","key":"10.7717\/peerj.20474\/ref-3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-2036.2005.02576.x","article-title":"Autoantibody profile during short-term infliximab treatment for Crohn\u2019s disease: a prospective cohort study","volume":"22","author":"Atzeni","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.7717\/peerj.20474\/ref-4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1586\/1744666x.4.2.275","article-title":"Autoantibody production in patients treated with anti-TNF-alpha","volume":"4","author":"Atzeni","year":"2008","journal-title":"Expert Review of Clinical Immunology"},{"issue":"7","key":"10.7717\/peerj.20474\/ref-5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.7717\/peerj.20474\/ref-6","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/ibd.20852","article-title":"Antinuclear antibodies: a marker associated with steroid dependence in patients with ulcerative colitis","volume":"15","author":"Barahona-Garrido","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"10.7717\/peerj.20474\/ref-7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ibd.21362","article-title":"Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-\u03b1 antibody-treated patients with inflammatory bowel disease","volume":"17","author":"Beigel","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.7717\/peerj.20474\/ref-8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fimmu.2015.00412","article-title":"Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014\u20132015","volume":"6","author":"Chan","year":"2015","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.7717\/peerj.20474\/ref-9","doi-asserted-by":"publisher","first-page":"e70419","DOI":"10.1111\/1756-185x.70419","article-title":"Case report: cryptococcal meningitis during tofacitinib therapy in ulcerative colitis: a rare opportunistic infection","volume":"28","author":"Chen","year":"2025","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"4","key":"10.7717\/peerj.20474\/ref-10","doi-asserted-by":"publisher","first-page":"17562848251375844","DOI":"10.1177\/17562848251375844","article-title":"Efficacy and safety of Risankizumab for moderate-to-severe Crohn\u2019s disease: first Asian real-world data (STAR trial)","volume":"18","author":"Chung","year":"2025","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"12","key":"10.7717\/peerj.20474\/ref-11","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1023\/a:1012702807714","article-title":"Spectrum of autoantibodies in celiac patients and relatives","volume":"46","author":"da Rosa Utiyama","year":"2001","journal-title":"Digestive Diseases and Sciences"},{"issue":"7","key":"10.7717\/peerj.20474\/ref-12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.7717\/peerj.20474\/ref-13","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/art.42330","article-title":"Increasing prevalence of antinuclear antibodies in the United States","volume":"74","author":"Dinse","year":"2022","journal-title":"Arthritis & Rheumatology"},{"issue":"8","key":"10.7717\/peerj.20474\/ref-14","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/biomedicines12081839","article-title":"Extraintestinal manifestations in inflammatory bowel disease: from pathophysiology to treatment","volume":"12","author":"Faggiani","year":"2024","journal-title":"Biomedicines"},{"issue":"5","key":"10.7717\/peerj.20474\/ref-15","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"10.7717\/peerj.20474\/ref-16","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1023\/a:1018832608899","article-title":"Antinuclear autoantibodies in patients with inflammatory bowel disease: high prevalence in first-degree relatives","volume":"42","author":"Folwaczny","year":"1997","journal-title":"Digestive Diseases and Sciences"},{"issue":"4","key":"10.7717\/peerj.20474\/ref-17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00042737-200304000-00003","article-title":"Development of antinuclear antibodies and its clinical impact in patients with Crohn\u2019s disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab)","volume":"15","author":"Garcia-Planella","year":"2003","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.7717\/peerj.20474\/ref-18","doi-asserted-by":"publisher","first-page":"17562848221077837","DOI":"10.1177\/17562848221077837","article-title":"Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy","volume":"15","author":"Garc\u00eda","year":"2022","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"10","key":"10.7717\/peerj.20474\/ref-19","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.7717\/peerj.20474\/ref-20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.curtheres.2014.06.004","article-title":"The prevalence of antinuclear antibodies in the general population of China: a cross-sectional study","volume":"76","author":"Guo","year":"2014","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"Suppl. 4","key":"10.7717\/peerj.20474\/ref-21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1046\/j.1365-2036.1999.00027.x","article-title":"Review article: safety of infliximab in clinical trials","volume":"13","author":"Hanauer","year":"1999","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"10.7717\/peerj.20474\/ref-22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/MPG.0b013e31802c6997","article-title":"Pediatric Crohn disease: clinical and genetic characteristics in Taiwan","volume":"44","author":"Hsiao","year":"2007","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"Suppl. A","key":"10.7717\/peerj.20474\/ref-23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jfma.2025.01.018","article-title":"Epidemiology and temporal trends of adult inflammatory bowel disease in Taiwan: multicenter study from the TSIBD registration","volume":"44","author":"Huang","year":"2025","journal-title":"Journal of the Formosan Medical Association"},{"issue":"6","key":"10.7717\/peerj.20474\/ref-24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/life15060893","article-title":"Serological assessment of hepatitis in patients with inflammatory bowel disease in Taiwan: a retrospective cohort analysis","volume":"15","author":"Lee","year":"2025","journal-title":"Life (Basel)"},{"issue":"8","key":"10.7717\/peerj.20474\/ref-25","doi-asserted-by":"publisher","first-page":"e22965","DOI":"10.1002\/jcla.22965","article-title":"Epidemiological survey of antinuclear antibodies in healthy population and analysis of clinical characteristics of positive population","volume":"33","author":"Li","year":"2019","journal-title":"Journal of Clinical Laboratory Analysis"},{"issue":"6","key":"10.7717\/peerj.20474\/ref-26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jfma.2024.06.004","article-title":"Diet and the risk of inflammatory bowel disease: a retrospective cohort study in Taiwan","volume":"124","author":"Meng","year":"2025","journal-title":"Journal of the Formosan Medical Association"},{"issue":"1","key":"10.7717\/peerj.20474\/ref-27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"5","key":"10.7717\/peerj.20474\/ref-28","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1097\/mib.0000000000000697","article-title":"The relevance of vitamin D and antinuclear antibodies in patients with inflammatory bowel disease under anti-TNF treatment: a prospective study","volume":"22","author":"Santos-Antunes","year":"2016","journal-title":"Inflammatory Bowel Diseases"},{"issue":"3","key":"10.7717\/peerj.20474\/ref-29","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00384-021-04091-6","article-title":"Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease","volume":"37","author":"Theodoraki","year":"2022","journal-title":"International Journal of Colorectal Disease"},{"issue":"4","key":"10.7717\/peerj.20474\/ref-30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/jgh.12496","article-title":"Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis\/perforating phenotype of Crohn\u2019s disease","volume":"29","author":"Tung","year":"2014","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"9","key":"10.7717\/peerj.20474\/ref-31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.autrev.2018.03.016","article-title":"Drug-induced lupus: traditional and new concepts","volume":"17","author":"Vaglio","year":"2018","journal-title":"Autoimmunity Reviews"},{"issue":"1","key":"10.7717\/peerj.20474\/ref-32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/s0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn\u2019s disease: a prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"issue":"2","key":"10.7717\/peerj.20474\/ref-33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.gtc.2008.03.001","article-title":"(Auto)antibodies in inflammatory bowel diseases","volume":"37","author":"Vermeire","year":"2008","journal-title":"Gastroenterology Clinics of North America"},{"issue":"3","key":"10.7717\/peerj.20474\/ref-34","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/aid2.13383","article-title":"Attitudes to medication and effects of IBD nursing service among patients with inflammatory bowel disease in Taiwan","volume":"11","author":"Yang","year":"2024","journal-title":"Advances in Digestive Medicine"},{"issue":"17","key":"10.7717\/peerj.20474\/ref-35","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.3390\/jcm11175050","article-title":"Radiation exposure among patients with inflammatory bowel disease: a single-medical-center retrospective analysis in Taiwan","volume":"11","author":"Yang","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"10.7717\/peerj.20474\/ref-36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/aid2.13300","article-title":"Real-world experience of adalimumab therapy for patients with ulcerative colitis: a single tertiary medical center experience in Central Taiwan","volume":"10","author":"Yen","year":"2023","journal-title":"Advances in Digestive Medicine"},{"issue":"3","key":"10.7717\/peerj.20474\/ref-37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5217\/ir.2023.00050","article-title":"Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023","volume":"22","author":"Yen","year":"2024","journal-title":"Intestinal Research"},{"issue":"2","key":"10.7717\/peerj.20474\/ref-38","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000199232","article-title":"Antibodies to the cytoskeleton components and other autoantibodies in inflammatory bowel disease","volume":"32","author":"Zauli","year":"1985","journal-title":"Digestion"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/20474.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20474.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20474.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:56:27Z","timestamp":1764320187000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/20474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":38,"alternative-id":["10.7717\/peerj.20474"],"URL":"https:\/\/doi.org\/10.7717\/peerj.20474","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"e20474"}}